Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

March of Dimes

This article was originally published in The Tan Sheet

Executive Summary

Lovastatin should not be switched over the counter "until there are more data on its safety in pregnancy," according to March of Dimes Medical Director Nancy Green, MD. Green notes that "some published data suggest lovastatin may be teratogenic," and that "widespread public recognition of statins may increase the likelihood of statin use during pregnancy." The FDA advisory panels discussed the pregnancy issue during their Jan. 13-14 meeting...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097742

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel